Joseph C. Scodari - 06 Jan 2025 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Reporting relationship: Director
Issuer ticker: ACXP
Reported as of: 06 Jan 2025
Net transaction value: +$25,000
SEC form: 4
Accepted by SEC: 08 Jan 2025, 16:32:30 UTC
Prior SEC filing: 18 Jun 2024
Next SEC filing: 22 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kostantinos Skordalos, Power of Attorney For: Joseph C. Scodari

Key filing fact

Joseph C. Scodari filed Form 4 for Acurx Pharmaceuticals, Inc. (ACXP) on 08 Jan 2025.

Key facts

This page summarizes Joseph C. Scodari's Form 4 filing for Acurx Pharmaceuticals, Inc. (ACXP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2025, 16:32.

Change

Previous filing in this sequence was filed on 18 Jun 2024.
Current net transaction value: +$25,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACXP transaction

Common Stock

Purchase

Transaction value: $25,000
Shares: +24,631
Change %: +800%
Price: $1.02
Shares after: 27,708
Date: 06 Jan 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACXP transaction Derivative

Warrants for Common Stock

Purchase

Transaction value: $0
Shares: +24,631
Change %
Price: $0.000000
Shares after: 24,631
Date: 06 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,631
Exercise price: $0.9000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Footnote F2

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.